{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:38:13Z","timestamp":1792791493855,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EY014800"],"award-info":[{"award-number":["EY014800"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajo.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ajo.2020.05.025","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T01:28:13Z","timestamp":1590197293000},"page":"208-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Retinopathy of Prematurity: Evolving Treatment With Anti\u2013Vascular Endothelial Growth Factor"],"prefix":"10.1016","volume":"218","author":[{"given":"M. Elizabeth","family":"Hartnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2020.05.025_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0002-9394(42)92088-9","article-title":"rhIGF-1\/rhIGFBP-3 in preterm infants: a phase 2 randomized controlled trial","volume":"25","author":"Terry","year":"1942","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2020.05.025_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.semperi.2019.05.001","article-title":"Retinopathy of prematurity\u2014a world update","volume":"43","author":"Darlow","year":"2019","journal-title":"Semin Perinatol"},{"issue":"26","key":"10.1016\/j.ajo.2020.05.025_bib3","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ajo.2020.05.025_bib4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s12098-009-0175-1","article-title":"Severe retinopathy of prematurity in big babies in India: history repeating itself?","volume":"76","author":"Shah","year":"2009","journal-title":"Indian J Pediatr"},{"issue":"11","key":"10.1016\/j.ajo.2020.05.025_bib5","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0161-6420(03)00831-5","article-title":"Telemedicine approach to screening for severe retinopathy of prematurity: a pilot study","volume":"110","author":"Ells","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2020.05.025_bib6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/bjo.38.7.433","article-title":"Direct observation of the effect of oxygen on developing vessels: preliminary report","volume":"38","author":"Ashton","year":"1954","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2020.05.025_bib7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1542\/peds.60.5.655","article-title":"PaO2 levels and retrolental fibroplasia: a report of the cooperative study","volume":"60","author":"Kinsey","year":"1977","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.ajo.2020.05.025_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3233\/NPM-190336","article-title":"Perinatal events predicting retinopathy of prematurity in extremely pre-term infants","volume":"13","author":"AlRyalat","year":"2020","journal-title":"J Neonatal Perinatal Med"},{"issue":"2","key":"10.1016\/j.ajo.2020.05.025_bib9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/sj.jp.7211040","article-title":"Arterial oxygen fluctuation and retinopathy of prematurity in very-low-birth-weight infants","volume":"24","author":"York","year":"2004","journal-title":"J Perinatol"},{"issue":"1","key":"10.1016\/j.ajo.2020.05.025_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jpeds.2010.01.046","article-title":"A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity","volume":"157","author":"Di Fiore","year":"2010","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.ajo.2020.05.025_bib11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/archophthalmol.2010.31","article-title":"Longitudinal postnatal weight measurements for the prediction of retinopathy of prematurity","volume":"128","author":"Wu","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2020.05.025_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000087586","article-title":"Oxidative stress in the newborn\u2014a 30-year perspective","volume":"88","author":"Saugstad","year":"2005","journal-title":"Biol Neonate"},{"issue":"21","key":"10.1016\/j.ajo.2020.05.025_bib13","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1001\/jama.2018.5725","article-title":"Association between oxygen saturation targeting and death or disability in extremely preterm infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration","volume":"319","author":"Askie","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ajo.2020.05.025_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group","volume":"106","year":"1988","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2020.05.025_bib15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archophthalmol.2010.72","article-title":"Final visual acuity results in the early treatment for retinopathy of prematurity study","volume":"128","author":"Good","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2020.05.025_bib16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0161-6420(93)31665-9","article-title":"Prognostic factors in the natural course of retinopathy of prematurity","volume":"100","author":"Schaffer","year":"1993","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ajo.2020.05.025_bib17","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0161-6420(91)32074-8","article-title":"Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group","volume":"98","author":"Palmer","year":"1991","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2020.05.025_bib18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/opo.12273","article-title":"Longitudinal imaging of microvascular remodelling in proliferative diabetic retinopathy using adaptive optics scanning light ophthalmoscopy","volume":"36","author":"Chui","year":"2016","journal-title":"Ophthalmic Physiol Opt"},{"issue":"8","key":"10.1016\/j.ajo.2020.05.025_bib19","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2011.01.003","article-title":"Ten-year longitudinal changes in retinal microvascular lesions: the Atherosclerosis Risk in Communities Study","volume":"118","author":"Liew","year":"2011","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2020.05.025_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10633-009-9181-x","article-title":"The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50\/10 OIR model","volume":"120","author":"Hartnett","year":"2010","journal-title":"Doc Ohthalmol"},{"key":"10.1016\/j.ajo.2020.05.025_bib21","first-page":"1201","article-title":"The effect of oxygen on vasoformative cell division: Evidence that \u201cphysiological hypoxia\u201d is the stimulus for normal retinal vasculogenesis","volume":"36","author":"Chan-Ling","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.ajo.2020.05.025_bib22","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","article-title":"Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors","volume":"124","author":"Huang","year":"2017","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2020.05.025_bib23","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2020.05.025_bib24","first-page":"CD003665","article-title":"Vitamin E supplementation for prevention of morbidity and mortality in preterm infants","author":"Brion","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.ajo.2020.05.025_bib25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10456-018-9618-5","article-title":"Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy","volume":"21","author":"Simmons","year":"2018","journal-title":"Angiogenesis"},{"issue":"4","key":"10.1016\/j.ajo.2020.05.025_bib26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood-2006-07-037952","article-title":"Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation","volume":"109","author":"Zeng","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ajo.2020.05.025_bib27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajo.2020.05.025_bib28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2020.05.025_bib29","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/jamaophthalmol.2017.2069","article-title":"Reduction of rod and cone function in 6.5-year-old children born extremely preterm","volume":"135","author":"Molnar","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2020.05.025_bib30","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.ophtha.2019.03.048","article-title":"Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: a prospective case-control study","volume":"126","author":"Fan","year":"2019","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2020.05.025_bib31","doi-asserted-by":"crossref","first-page":"e20183537","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment","volume":"144","author":"Natarajan","year":"2019","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.ajo.2020.05.025_bib32","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ophtha.2019.06.001","article-title":"Are we closer to understanding developmental outcomes from intravitreal bevacizumab therapy for retinopathy of prematurity?","volume":"126","author":"Carden","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2020.05.025_bib33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1907423","article-title":"A randomized trial of erythropoietin for neuroprotection in preterm infants","volume":"382","author":"Juul","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajo.2020.05.025_bib34","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41598-018-20278-4","article-title":"Targeted knockdown of overexpressed VEGFA or VEGF164 in Muller cells maintains retinal function by triggering different signaling mechanisms","volume":"8","author":"Becker","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ajo.2020.05.025_bib35","first-page":"CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"10208","key":"10.1016\/j.ajo.2020.05.025_bib36","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ajo.2020.05.025_bib37","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2020.05.025_bib38","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s10792-018-1040-x","article-title":"Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by periodic fluorescence angiography and optical coherence tomography","volume":"39","author":"Vural","year":"2019","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ajo.2020.05.025_bib39","doi-asserted-by":"crossref","first-page":"xiv","DOI":"10.1016\/j.ajo.2018.05.013","article-title":"Systemic solutions in retinopathy of prematurity","volume":"193","author":"Moshfeghi","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2020.05.025_bib40","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/jamaophthalmol.2018.1934","article-title":"Automated diagnosis of plus disease in retinopathy of prematurity using deep convolutional neural networks","volume":"136","author":"Brown","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2020.05.025_bib41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jpeds.2018.10.033","article-title":"rhIGF-1\/rhIGFBP-3 in preterm infants: a phase 2 randomized controlled trial","volume":"206","author":"Ley","year":"2019","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.ajo.2020.05.025_bib42","doi-asserted-by":"crossref","first-page":"e202239","DOI":"10.1001\/jamanetworkopen.2020.2239","article-title":"Is the environment associated with preterm birth?","volume":"3","author":"Etzel","year":"2020","journal-title":"JAMA Netw Open"}],"updated-by":[{"DOI":"10.1016\/j.ajo.2020.12.018","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000}}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939420302646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939420302646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T17:40:51Z","timestamp":1666633251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939420302646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":42,"alternative-id":["S0002939420302646"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2020.05.025","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ajo.2020.12.018","asserted-by":"object"}]},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retinopathy of Prematurity: Evolving Treatment With Anti\u2013Vascular Endothelial Growth Factor","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2020.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}